Overview
PLAID syndrome (PLCγ2‑associated antibody deficiency and immune dysregulation) is a rare, inherited primary immunodeficiency disorder caused by gain‑of‑function mutations in the PLCG2 gene, which encodes phospholipase C gamma 2 (PLCγ2). The condition is characterized by a combination of immune dysregulation, antibody deficiency, and cutaneous cold‑induced urticaria.
Genetics and Pathophysiology
- Gene: Mutations are typically heterozygous missense variants in the PLCG2 gene located on chromosome 16q23.3.
- Inheritance: Autosomal dominant with variable penetrance; most cases arise from de novo mutations.
- Mechanism: The mutant PLCγ2 protein exhibits hyper‑responsive signaling at sub‑physiological temperatures, leading to abnormal activation of B‑cell receptors and downstream pathways. This results in dysregulated immune cell function, impaired antibody production, and heightened mast cell degranulation upon cold exposure.
Clinical Features
| System | Typical Manifestations |
|---|---|
| Dermatologic | Cold‑induced urticaria and rash that appear after exposure to temperatures below ~20 °C; often the earliest sign in childhood. |
| Immunologic | Low levels of serum IgG and IgM, with variable IgA; elevated IgE in many patients. Recurrent sinopulmonary infections are common. |
| Hematologic | Lymphopenia, especially of memory B cells; occasional autoimmune cytopenias. |
| Other | Eczematous dermatitis, mild atopic features, and occasional bronchiectasis secondary to chronic infections. |
Diagnosis
- Clinical evaluation of characteristic cold‑induced urticaria and recurrent infections.
- Laboratory assessment including quantitative immunoglobulins (typically low IgG/IgM, high IgE), specific antibody responses to vaccines, and lymphocyte subset analysis.
- Genetic testing confirming a pathogenic PLCG2 gain‑of‑function variant.
Management
- Infection prophylaxis: Regular immunoglobulin replacement therapy (IVIG or subcutaneous) to correct antibody deficiency.
- Allergy control: Antihistamines and avoidance of cold exposure; in severe cases, omalizumab has been reported to reduce urticarial episodes.
- Vaccination: Inactivated vaccines are recommended; live vaccines are used cautiously due to variable immune competence.
- Monitoring: Periodic assessment of lung function and imaging to detect early bronchiectasis, as well as surveillance for autoimmune complications.
Epidemiology
PLAID syndrome is extremely rare, with fewer than 50 genetically confirmed cases reported in the medical literature worldwide as of the early 2020s. The precise prevalence is unknown.
History
The disorder was first described in 2012 by researchers identifying a familial cohort with cold‑induced urticaria, antibody deficiency, and a shared PLCG2 mutation. The acronym PLAID was coined to reflect the core clinical triad of PLCγ2‑associated Antibody deficiency and Immune Dysregulation. Subsequent studies have elucidated the molecular basis and expanded the phenotypic spectrum.
Research Directions
Current investigations focus on:
- Elucidating the precise signaling alterations caused by mutant PLCγ2.
- Evaluating targeted therapies that modulate PLCγ2 activity or downstream pathways.
- Long‑term outcomes of immunoglobulin replacement and biologic agents in preventing organ damage.
References
(References are omitted here but information is derived from peer‑reviewed articles in immunology and clinical genetics journals.)